AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Bruno CHAUFFERT, Department of Oncology-Hematology, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France.
Citation: Bruno CHAUFFERT, Marion GOGNARD, Abdenour OUIKENE, Mohamad CHEHIMI, Agnes GALEZ et. al., (2024), Weekly carboplatin, paclitaxel and cetuximab with pembrolizumab every 3 weeks is active and tolerated in patients with locally advanced and/or metastatic/recurrent head and neck squamous cell carcinoma, J Cancer Research and Cellular Therapeutics, 8(1); DOI:10.31579/2640-1053/185
Copyright: © 2024, Bruno CHAUFFERT. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 08 February 2024 | Accepted: 16 February 2024 | Published: 26 February 2024
Keywords: pembrolizumab; cetuximab; paclitaxel; carboplatin; head and neck squamous cell carcinoma
The management of recurrent/metastatic head and neck carcinoma (R/M HNSCC) is evolving with new available molecules and combination modalities. Anti-EGFR cetuximab and immune checkpoint inhibitors (ICI) are used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluorouracil). Few data have been reported on the combination of doublet chemotherapy with both cetuximab and ICI. Here, we review a series of 17 patients that received a quadritherapy (QT) with paclitaxel, 60 mg/m2/week, carboplatin, AUC 1.5/week, cetuximab, 250 mg/m2 /week, and pembrolizumab, 200 mg every 3 weeks. Nine to 12 weekly injections were done before evaluation by clinical examination and PET-CT. Nine patients with bulky advanced disease responded to QT (3 complete responses (CR), 6 partial responses (PR)). Seven patients further received a cisplatin-based chemoradiotherapy (CRT). Eight out of nine patients are still in CR. Eight patients received QT for recurrent and/or metastatic disease. One CR, 3 PR and 3 stable diseases were recorded. Adverse events were minor, except for an ICI-related grade 3 cardiac toxicity. Overall, this short series indicates that QT with weekly carboplatin-paclitaxel-cetuximab and pembrolizumab every 3 weeks is safe and active in patients with advanced or R/M HNSCC. These results should be confirmed through further randomized trials.
Head and neck squamous cell carcinoma (HNSCC) are usually treated with curative intention by surgery and/or concomitant chemoradiotherapy (CRT). However, a fraction of patients will relapse with distant metastases and/or locoregional recurrence. About 5% of patients present with upfront metastases [1]. In some cases, patients present with a bulky local and/or regional disease, mostly cervical nodes. The TPF regimen (docetaxel, cisplatin and fluorouracil) is then used as a neodjuvant approach before CRT (2). However, TPF is not well tolerated and cannot be used in frail patients. The EXTREME protocol (cisplatin or carboplatin, fluorouracil, and cetuximab, followed by weekly cetuximab maintenance) is still considered to be the standard first-line treatment for R/M HNSCC [3]. However, the side effects of six cycles of EXTREME limit its administration to fit patients. The TPEX protocol (cisplatin-docetaxel-cetuximab) for 4 cycles and cetuximab maintenance did not improve the overall survival, but it led to fewer toxicities than the EXTREME protocol [4]. The non-inferiority and better tolerance of carboplatin-paclitaxel-cetuximab compared to the EXTREME regimen was reported [5]. After decades of therapeutic stagnation, immunotherapy has transformed the field of cancer therapeutics. The KEYNOTE-048 phase III study established that pembrolizumab, an anti-PD1 antibody, plus standard chemotherapy with platinum and 5-fluorouracil is an appropriate first-line treatment for R/M HNSCC [6]. However, only 15-20% of patients ultimately benefit from anti-PD1 alone or in combination with chemotherapy, highlighting the need to improve the efficacy of immune checkpoint inhibitors for HNSCC treatment. A phase II trial reported that the combination of pembrolizumab and cetuximab is active and safe [7]. However, combinations of the most active agents in HNSCC, such as platinum-based doublet with taxane combined with cetuximab and cisplatin is a option to explore. Last year, we published a case series on 8 patients that received carboplatin-paclitaxel-cetuximab-pembrolizumab (quadritherapy) using a 3 weekly regimen [8]. The response rate was impressive (8/8) in selected patients. We have modified the protocol so that it was suitable for all patients, particularly frail patients, by using weekly carboplatin, paclitaxel, cetuximab and pembrolizumab every 3 weeks. The aim of the present study is to report the results of this new regimen on a series of 17 consecutive patients, with locally advanced or metastatic/recurrent disease.
Patients were treated at our institution from March 2022 to December 2023. All patients had pathologically confirmed HNSCC and were not immediately suitable for curative therapy (surgery and/or CRT). None had been treated before, except for patients that had disease recurrence after previous radiotherapy with concomitant cisplatin or carboplatin. All patients were smokers and had a negative p16 status. The PD-L1 score was not taken into account for the prescription of pembrolizumab. Patients were informed by the investigators about the exploratory aspect of this regimen. Treatment was validated by the specialized medical committee for head and neck carcinomas in our institution. Weekly quadruplet (termed hereafter QT) consisted of paclitaxel (60 mg/m2/wk), carboplatin (AUC 1.5 mg/mL/min/wk) and cetuximab (250 mg/m2/wk). Pembrolizumab (200 mg) was given every 3 weeks. All drugs are approved and available in France for R/M HNSCC. Patients received 9 to 12 weekly injections before evaluation by clinical examination with nasofibroscopy and positron emission tomography-computed tomography (PET-CT). Tumor response was scored both by RECIST [9] and PERCIST score [10], for clinical evaluation and PET-CT, respectively. If stable, partial or complete response was observed, pembrolizumab 200 mg was pursued every 3 weeks until progression in reccurent/metastatic patients. In patients with locally advanced disease at the initial time, radiotherapy with either cisplatin or carboplatin was done with no further treatment.
17 consecutive patients received QT. Nine had a locally advanced disease not allowing for initial CRT due to large tumor volume (Table 1). All tumors responded (6 PR, 3 CR) to induction QT, so that a CRT with concomitant cisplatin or carboplatin could be completed in 7/9 patients. One patient in CR refused RT. Radiotherapy was unfeasible for a patient with a neck deformation. Clinical response was quickly observed, most often after a month of QT. All patients are alive without disease on December 31, 2023.
| Gender (Age) | Localization (TNM) | Toxicity of QT (grade) | Response after QT | Response after CRT | Overall survival (months) | |
| 1 | M (50) | Basis of tongue (T3N2M0) | CR | CR | 18 (+) | |
| 2 | M (61) | Pelvilingual cervical nodes (T4N2M0) | PR | CR | 16 (+) | |
| 3 | M (64) | Maxillary sinus (T4NOM0) | PR | CR | 15 (+) | |
| 4 | M (73) | Oropharynx, cervical, mediastinal nodes (T2N3M1) | skin (2) | PR | CR | 7 (+) |
| 5 | M (49) | Larynx, cervical nodes (T3N1M0) | CR | CR | 7 (+) | |
| 6 | F (66) | Pharynx, cervical nodes (T4N2M0) | PR | PR | 6 (+) | |
| 7 | F (67) | Pelvilingual, cervical nodes (T3N2M0) | skin (2), cardiac (3) | CR | RT not done | 6 (+) |
| 8 | M (76) | Larynx, cervical nodes (T2N3M0) | PR | CR | 5 (+) | |
| 9 | M (70) | Cervical nodes (T0N3M0) | PR | RT not done | 5 (+) |
Figure 1: Results of neo-adjuvant use of weekly quadritherapy (QT).
CR: complete response. PR: partial response.CRT: chemoradiotherapy. +: indicates that patients are alive on December 31, 2023.
Six patients had local recurrence and/or metastases after previous CRT and 2 patients had initial metastases (Table 2). One complete response, 3 partial responses and 3 stable diseases were observed. Only one patient had progression on QT. Four patients out of eight were alive on December 31, 2023. Three had persistent disease and received a second line of treatment.
| Gender (age) | Initial localization (TNM) | Previous treatment | Site of recurrence/metastases | Toxicity (grade) | Best response after QT | Time of Disease Control by QT then pembro-lizumab maintenance (months) | Overall Survival (months) |
| M (69) | Pelvilingual (T3N2M0) | RT / cisPt | local, lung | SD | 14 | 17 (+) | |
| M (72) | Pelvilingual (T4N1M0) | RT/carbopt | local, lung | PR | 15 (+) | 15 (+) | |
| M (45) | Oropharynx (T3N2M0) | RT/cisPt | local, lung | CR | 6 | 13 (+) | |
| M (57) | Pharynx (T3N0M1) | local, mediastinal lombo-aortic nodes | skin (1) | PR | 8 | 10 (D) | |
| M (64) | Larynx (T4N2M0) | RT/carboPt | local, lung, mediastinal | skin (2) | PR | 4 | 5 (D) |
| M (55) | Larynx (T4N0M0) | Surgery + RT | lung | skin (2) | SD | 7 | 7 (+) |
| M (86) | Cervical nodes (T0N3M0) | lung, mediastinal nodes | PROG | 2 | 5 (D) | ||
| M (56) | Oropharynx (T3N2M0) | RT/cispt | lung, mediastinal nodes | skin (1) | SD | 3 | 4 (D) |
Table 2: Results of weekly QT in patients with recurrent and/or metastatic disease.
Cispt: cisplatin. Carbopt: carboplatin. CR: complete response. PR: partial response. SD: stable disease. PROG: progressive disease. D indicates that patients are dead. + : indicates that patients are alive on December 31, 2023.
Six patients had grade1- 2 cutaneous toxicity related to cetuximab. Oral cyclin antibiotic and local steroids permitted the continuation of the regimen. A pembrolizumab-related cardiac grade 3 myocarditis was recorded in a female patient with increased levels of troponin and 20 percent decrease of the ventricular ejection fraction. Cardiac toxicity was reversible with steroids after discontinuation of pembrolizumab. No other toxicity related to the immune checkpoint inhibitor (ICI) therapy occurred. No major hematological toxicity occurred due to the low doses of weekly carboplatin and paclitaxel. In some cases, there was a one week deferral of the planned cure and use of granulocyte stimulating factor.
The present series presents results from a new weekly regimen of paclitaxel, carboplatin, cetuximab with concomitant pembrolizumab as ICI. The complete or partial response rate was higher in the neo-adjuvant cohort (9/9) than in patients with recurrence and/or metastases (4/8). Only 1 patient had progressive disease on QT. Toxicity was low, except for a reversible grade III myocarditis related to pembrolizumab. Hematological tolerance was good due to the weekly regimen of carboplatin and paclitaxel. The lower toxicity of weekly carboplatin and paclitaxel, in combination with cetuximab, with equivalent efficacy to a tri-weekly administration that was reported earlier [11]. By comparison, the response rates for standard protocols were 36% and 59% in the EXTREME (platinum salt, fluorouracil, cetuximab) and TPEx (docetaxel, platinum salt, cetuximab) trials, respectively [3,4]. In the keynote-048 study, response rate to pembrolizumab monotherapy was 17%, which increased to 36% when pembrolizumab was combined with a standard cisplatin/fluorouracil chemotherapy regimen [7].
Triplet therapy with a taxane, carboplatin and cetuximab had soon been explored with encouraging results [12]. The triplet was used in a neoadjuvant setting in a case series of 24 previously untreated patients, who were unfit to receive the TPF protocol [13]. The response rate was 87 percent after 3 cycles of the PCE protocol, and some patients benefited from a locoregional curative treatment. Carboplatin, paclitaxel, and cetuximab were also used on a weekly regimen with a good tolerance in frail patients with R/M HNSCC. A 43% overall response rate was recorded in 60 patients [14].
Triplet of paclitaxel, carboplatin and an ICI were also investigated. Safety and preliminary activity of pembrolizumab and weekly carboplatin-paclitaxel were evaluated in 8 heavily pretreated and/or fragile patients with recurrent/metastatic head and neck cancer. Disease control rate was 43%, with little toxicity [15].Neoadjuvant chemo-immunotherapy with carboplatin, nab-paclitaxel, and durvalumab produced a 57% response rate in patients with resectable locally advanced HNSCC [16].
Few quadruplets of chemotherapy with both cetuximab and an ICI have been reported. Weekly paclitaxel, carboplatin, cetuximab (PCE) followed by nivolumab as ICI led to a 48% response rate in recurrent/metastatic HNSCC patients. However, ICI was used following but not concomitantly with chemotherapy and cetuximab [17]. At our knowledge, we were the first to report a high response rate (8/8] with a concomitant quadruplet using 3 weekly administration of paclitaxel, carboplatin pembrolizumab with weekly cetuximab [8]. The present series on 17 new patients confirm the high response rate to a weekly quadruplet and its good tolerance.
Activation of sustained innate immunity by cetuximab through NK activation and antibody-dependent complement cytotoxicity (ADCC) could explain its synergy with the PD1 inhibitors, as was for example reported in NSCLC patients [18].
Our second series confirmed that quadritherapy seems active and tolerated in the first-line treatment of locally advanced, or recurrent/metastatic HNSCC. The additive role of combining an anti-PD1 antibody to a paclitaxel/carboplatin/cetuximab backbone should be investigated in prospective randomized trials.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
